Liquidia Corporation LQDA

LQDA Company Overview

Liquidia Corporation is a U.S.-based biopharmaceutical company focused on the development, manufacturing, and commercialization of therapies for pulmonary hypertension and other cardiopulmonary diseases. The company operates primarily within the biotechnology and specialty pharmaceutical industries, with a strategic emphasis on rare disease markets. Its core revenue and value drivers center on inhaled therapeutics developed using its proprietary particle engineering platform technology, designed to optimize drug delivery, efficacy, and manufacturing scalability.

The company’s principal product candidate is YUTREPIA, an inhaled dry-powder formulation of treprostinil intended for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia also commercializes products and services through Liquidia PAH, LLC and maintains proprietary technology through its PRINT particle engineering platform. Founded in 2004 and later becoming a publicly traded company on Nasdaq under the ticker LQDA, Liquidia evolved from a platform-focused nanotechnology company into a commercial-stage biopharmaceutical business concentrated on pulmonary hypertension therapies and specialty drug delivery systems.